Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Commences Thalomid Patent Litigation Against Barr

This article was originally published in The Pink Sheet Daily

Executive Summary

Lawsuit triggers 30-month stay of FDA action on generic thalidomide.

You may also be interested in...



Will REMS Delay Generics? Revlimid Petition May Help Determine The Answer

Dr. Reddy’s asks FDA to spell out policy to assure that new Risk Evaluation and Mitigation Strategies will be used to block generics. Celgene’s refusal to make Revlimid available for bioequivalence study is at issue.

Will REMS Delay Generics? Revlimid Petition May Help Determine The Answer

Dr. Reddy’s asks FDA to spell out policy to assure that new Risk Evaluation and Mitigation Strategies will be used to block generics. Celgene’s refusal to make Revlimid available for bioequivalence study is at issue.

Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly

Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.

Related Content

Topics

UsernamePublicRestriction

Register

PS065069

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel